Evaluating the safety profile of semaglutide: an updated meta-analysis.
Frederick Berro RiveraEloise Arias-AguirreZedrick AguirreMc John C YbañezJanos Marc M RubiaDanica Janine GalangGrace Nooriza LumbangJade Monica Marie J RuyerasJohn Vincent MagalongPolyn Luz PineJohn Andrew C AmigoMarie Francesca M AnsayNenad ZelenkovSteve Samuel ThomasKrishnaswami VijayaraghavanPublished in: Current medical research and opinion (2024)
Semaglutide appears to have a favorable safety profile across diverse patient populations and treatment durations, supporting its continued use in the management of type 2 diabetes mellitus and obesity. It is generally well-tolerated, with a low incidence of adverse events. Clinicians should be aware of these findings and monitor patients accordingly. Further long-term studies are warranted to assess the safety of semaglutide in clinical practice.
Keyphrases
- systematic review
- end stage renal disease
- clinical practice
- chronic kidney disease
- metabolic syndrome
- newly diagnosed
- ejection fraction
- type diabetes
- insulin resistance
- case control
- peritoneal dialysis
- weight loss
- case report
- palliative care
- risk factors
- prognostic factors
- randomized controlled trial
- meta analyses
- body mass index
- weight gain
- physical activity
- smoking cessation
- patient reported
- genetic diversity